CB

Caelum Biotech

High
Life Sciences · Life Sciences · Boston, US · Broker Lockton · UW R. Tanaka
GWP
$2.10M
Renewal in
47d
Loss ratio
41%
YoY
+28%+28%
Open claims
1
Cross-sell
$1.40M
Client intelligence
What's happening at the client
Phase III oncology trial reads out positive
  • Phase III oncology trial reads out positive
    2026-06-12
  • FDA approval expected Q4 for lead asset
    2026-05-18
Industry trend
Where the market is moving
Life sciences product liability
  • Life sciences product liability
    0% YoY
    Pricing flat as capacity returns
  • Clinical trials L&G
    +18%
    Asia trial volume +18%
Emerging risks
On the horizon
AI-derived diagnostics liability
  • AI-derived diagnostics liability
    Medium
    New AI imaging product
  • Bio-IP theft via cyber
    High
    Recent peer breach incidents
AI synthesis
Market & risk brief
AI